Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemfibrozil - Forest Hills Lab

X
Drug Profile

Gemfibrozil - Forest Hills Lab

Alternative Names: FHL-301

Latest Information Update: 17 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Forest Hills Lab
  • Class Antihyperlipidaemics; Antiparkinsonians; Ethers; Fibric acid derivatives; Pentanoic acids
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 17 Jan 2024 Phase-II clinical trials in Parkinson's disease in USA (PO) prior to January 2024 (Forest Hills Lab pipeline, January 2024)
  • 10 Jul 2023 Preclinical trials in Parkinson's disease in China (PO)
  • 27 Jun 2023 Forest Hills Lab plans a phase II trial for Parkinson's disease (In adults, In the elderly) (PO) in November 2023 (NCT05931484)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top